Multi-faceted enhancement of full-thickness skin wound healing by treatment with autologous micro skin tissue columns

Abstract Impaired wound healing is an immense medical challenge, and while autologous skin grafting remains the “gold-standard” therapeutic option for repairing wounds that cannot be closed by primary or secondary intention, it is limited by substantial donor site morbidity. We previously developed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christiane Fuchs, Linh Pham, Jermaine Henderson, Katherine J. Stalnaker, R. Rox Anderson, Joshua Tam
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/47e2cf79e6ba418886e310ad08841f72
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Impaired wound healing is an immense medical challenge, and while autologous skin grafting remains the “gold-standard” therapeutic option for repairing wounds that cannot be closed by primary or secondary intention, it is limited by substantial donor site morbidity. We previously developed the alternative approach of harvesting full-thickness skin tissue in the form of “micro skin tissue columns” (MSTCs), without causing scarring or any other long-term morbidity. In this study we investigated how MSTC treatment affects the different cellular processes involved in wound healing. We found that MSTC-derived cells were able to remodel and repopulate the wound volume, and positively impact multiple aspects of the wound healing process, including accelerating re-epithelialization by providing multiple cell sources throughout the wound area, increasing collagen deposition, enhancing dermal remodeling, and attenuating the inflammatory response. These effects combined to enhance both epidermal and dermal wound healing. This MSTC treatment approach was designed for practical clinical use, could convey many benefits of autologous skin grafting, and avoids the major drawback of donor site morbidity.